Home›Adalimumab Bwwd›Adalimumab Bwwd + Adalimumab

Does Adalimumab Bwwd Interact with Adalimumab?

Adalimumab Bwwd and Adalimumab have a major drug interaction according to U.S. FDA drug labeling data. 7 DRUG INTERACTIONS • Abatacept: Increased risk of serious infection ( 5.1 , 5.11 , 7.2 ) • Anakinra: Increased risk of serious infection ( 5.1 , 5.7 , 7.2 ) • Live vaccines: Avoid use with HADLIMA ( 5.10 , 7.3 ) 7.1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either HADLIMA or MTX [see Clinical Pharmacology ( 12.3 )] . It is possible for products that antagonize cytokine activity, such as adalimumab products, to influence the formation of CYP450 enzymes. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Adalimumab Bwwd Class
Tumor Necrosis Factor Blocker
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Adalimumab Bwwd and your doctor is considering prescribing Adalimumab (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Adalimumab Bwwd(Hadlima)+💊 Adalimumab(Amjevita)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
Tumor Necrosis Factor Blocker
Drug B class
—
Source
FDA drug label - adalimumab-bwwd

What this means in plain English

7 DRUG INTERACTIONS • Abatacept: Increased risk of serious infection ( 5.1 , 5.11 , 7.2 ) • Anakinra: Increased risk of serious infection ( 5.1 , 5.7 , 7.2 ) • Live vaccines: Avoid use with HADLIMA ( 5.10 , 7.3 ) 7.1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either HADLIMA or MTX [see Clinical Pharmacology ( 12.3 )] . It is possible for products that antagonize cytokine activity, such as adalimumab products, to influence the formation of CYP450 enzymes.

About Adalimumab Bwwd and Adalimumab

Adalimumab Bwwd is a Tumor Necrosis Factor Blocker. You may recognize them by the brand names Hadlima and Amjevita. Both medications are given by injection under the skin. Both Adalimumab Bwwd and Adalimumab carry an FDA boxed warning — the agency's most serious safety designation.

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Adalimumab Bwwd and Adalimumab against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.